First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

Objective This study aimed to assess the cost-effectiveness of two recently approved first-line chemo-immunotherapies [atezolizumab combined with etoposide and platinum (AEP) and durvalumab combined with etoposide and platinum (DEP)] for patients with extensive-stage small-cell lung cancer (ES-SCLC)...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in oncology 2021-06, Vol.11, p.699781-699781, Article 699781
Hauptverfasser:	Liu, Qiao, Luo, Xia, Yi, Lidan, Zeng, Xiaohui, Tan, Chongqing
Format:	Artikel
Sprache:	eng
Schlagworte:	atezolizumab cost-effectiveness durvalumab etoposide-platinum extensive-stage small-cell lung cancer Life Sciences & Biomedicine Oncology Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!